Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2015-05-12 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
重大事项停牌进展公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement from Jiangsu Sihuan Bio Co., Ltd. regarding the progress of a trading suspension due to planning a non-public stock issuance. It mentions the stock suspension dates and ongoing due diligence but does not contain financial statements or detailed financial data. The document length is only 514 characters, indicating it is a brief announcement rather than a full report. The content focuses on capital raising activities and stock suspension updates, which aligns with a Capital/Financing Update. It is not a full financial report, earnings release, or regulatory certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2015-05-12 Chinese
关于委托贷款提前收回的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement regarding the early repayment of a entrusted loan by a subsidiary of the company. It includes details about the loan amount, interest rate, term, and the fact that the loan was repaid early. The document is brief (588 characters) and serves as a notification to shareholders and the public about this financial event. It does not contain financial statements, detailed financial analysis, or comprehensive report content. It is not an annual report, interim report, earnings release, or any detailed financial filing. It is also not a regulatory certification or officer attestation. The content fits best as a Capital/Financing Update since it informs about a financing activity (loan repayment).
2015-05-12 Chinese
关于全资子公司获得药品GMP证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding a subsidiary obtaining a GMP certificate, issued by a regulatory authority. It is a formal disclosure but does not contain financial data, management changes, or detailed reports. The length is only 574 characters, indicating it is a brief announcement rather than a full report. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is a regulatory announcement about compliance and certification, so it best fits under Regulatory Filings (RNS).
2015-05-12 Chinese
2015年第一季度报告的更正公告
Regulatory Filings Classification · 95% confidence The document is a correction announcement related to the company's previously disclosed 2015 first quarter report. It specifically corrects a data error regarding the number of ordinary shareholders at the end of the reporting period. The document is very short (398 characters) and does not contain substantive financial data or the full report itself. It is an announcement correcting information in a previously released interim/quarterly report, not the report itself. Therefore, it fits best as a Regulatory Filing (RNS), which covers miscellaneous announcements and corrections that do not constitute the full report.
2015-05-05 Chinese
2015年第一季度报告正文（更新后）
Interim / Quarterly Report Classification · 100% confidence The document is titled '江苏四环生物股份有限公司 2015 年第一季度报告正文' which translates to 'Jiangsu Sihuan Biological Co., Ltd. 2015 First Quarter Report'. It contains detailed financial data for the first quarter of 2015, including income, net profit, cash flow, shareholder information, and explanations of financial changes. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (quarterly) indicates this is an Interim / Quarterly Report. The document length is 7329 characters, which is sufficient to contain substantive financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2015
2015-05-05 Chinese
重大事项停牌进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Jiangsu Sihuan Bio Co., Ltd. regarding the progress of a trading suspension due to a major matter, specifically a non-public issuance of shares. It mentions that the company is still finalizing the plan and requests continued suspension of trading. The document is short (531 characters) and serves as an update on a capital raising event, not a full financial report or detailed filing. This fits the category of a Capital/Financing Update (CAP) as it relates to fundraising activities and capital structure changes.
2015-05-05 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.